ARGENICA THERAPEUTICS LIMITED - Announcements

Market Cap $73.07M Add to my watchlist

Healthcare

Argenica Therapeutics Limited is an Australia-based clinical drug development company.... Argenica Therapeutics Limited is an Australia-based clinical drug development company. The Company is focused on developing therapeutics to reduce brain tissue death after stroke and other types of brain injury and neurodegenerative diseases to improve patient outcomes. The Company's lead candidate, ARG-007, is a cationic arginine-rich peptide that aims to protect brain cells and reduce cell death following a stroke, and other types of neural injury, in order to minimize the impact of these conditions and improve patient recovery. ARG-007 has been successfully demonstrated to improve outcomes in pre-clinical stroke models, traumatic brain injury (TBI) and hypoxic ischaemic encephalopathy (HIE). More

Announcements

Filter Results

All Price Sensitive Only

AGN	DSMB Confirms Safety of First Patients Dosed	PRICE SENSITIVE	29/04/24	263.85KB	Share
AGN	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	24/04/24	375.6KB	Share
AGN	Cleansing Notice		22/04/24	178.19KB	Share
AGN	Application for quotation of securities - AGN		22/04/24	15.55KB	Share
AGN	Proposed issue of securities - AGN		12/04/24	16.9KB	Share
AGN	Proposed issue of securities - AGN		12/04/24	15.74KB	Share
AGN	Argenica Successfully Completes $12.0m Placement	PRICE SENSITIVE	12/04/24	224.26KB	Share
AGN	Trading Halt	PRICE SENSITIVE	10/04/24	298.63KB	Share
AGN	Patient Dosing Milestone Achieved in Phase 2 Stroke Trial	PRICE SENSITIVE	10/04/24	275.78KB	Share
AGN	First Patient Dosed in Phase 2 Stroke Trial of ARG-007	PRICE SENSITIVE	28/03/24	289.42KB	Share
AGN	FDA Grants Rare Pediatric Disease Designation For HIE	PRICE SENSITIVE	25/03/24	203.44KB	Share
AGN	Application for quotation of securities - AGN		07/03/24	15.58KB	Share
AGN	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/24	706.71KB	Share
AGN	Application for quotation of securities - AGN		16/02/24	15.58KB	Share
AGN	Phase 2 Manufacturing Completed & Trial Update	PRICE SENSITIVE	12/02/24	252.98KB	Share
AGN	Cleansing Notice		02/02/24	190.16KB	Share
AGN	Application for quotation of securities - AGN		02/02/24	24.9KB	Share
AGN	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/24	427.2KB	Share
AGN	Phase 2 Stroke Clinical Trial Update	PRICE SENSITIVE	14/12/23	275.23KB	Share
AGN	AGM Presentation		01/12/23	3.16MB	Share
AGN	Initial Director's Interest Notice		01/12/23	263.51KB	Share
AGN	Final Director's Interest Notice		01/12/23	253.78KB	Share
AGN	Amended Constitution		01/12/23	599.05KB	Share
AGN	Results of Annual General Meeting		01/12/23	244.69KB	Share
AGN	Appointment of Non-Executive Chair	PRICE SENSITIVE	30/11/23	196.34KB	Share
AGN	Argenica Appoints VP of Business Development		22/11/23	195.34KB	Share
AGN	FDA Grants Orphan Drug Designation for ARG-007 HIE Treatment	PRICE SENSITIVE	15/11/23	221.17KB	Share
AGN	Argenica Receives $2.09m R&D Tax Incentive Cash Rebate	PRICE SENSITIVE	13/11/23	183.74KB	Share
AGN	ARG-007 Inhibits Cause of Alzheimer's in Pre-Clinical Study	PRICE SENSITIVE	03/11/23	391.65KB	Share
AGN	Board Update		27/10/23	251.03KB	Share
AGN	Notice of Annual General Meeting/Proxy Form		27/10/23	705.69KB	Share
AGN	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	26/10/23	445.53KB	Share
AGN	Investor Presentation		25/10/23	1.78MB	Share
AGN	Preclinical HIE Study - ARG007 Effective Stand-Alone Therapy	PRICE SENSITIVE	18/10/23	456.12KB	Share
AGN	Date of AGM & Closing Date For Director Nominations		29/09/23	200.98KB	Share
AGN	Ethics Approval Received for Phase 2 Trial	PRICE SENSITIVE	12/09/23	281.35KB	Share
AGN	Grant Awarded To Develop Additional Administration Route	PRICE SENSITIVE	12/09/23	254.53KB	Share
AGN	Presentation - Fetal and Neonatal Scientific Conference		04/09/23	1.49MB	Share
AGN	Presentation - Stroke 2023 Scientific Conference		24/08/23	2.05MB	Share
AGN	Positive FDA Feedback Following Pre-Ind Meeting	PRICE SENSITIVE	23/08/23	219.86KB	Share
AGN	Appendix 4G & Corporate Governance Statement		23/08/23	515.83KB	Share
AGN	Appendix 4E & Annual Report 30 June 2023	PRICE SENSITIVE	23/08/23	1020.23KB	Share
AGN	Response to ASX Aware Query	PRICE SENSITIVE	18/08/23	354.09KB	Share
AGN	Cleansing Notice		03/08/23	177.85KB	Share
AGN	Application for quotation of securities - AGN		03/08/23	24.8KB	Share
AGN	ARG-007 Prevents Uptake & Aggregation of Key Protein	PRICE SENSITIVE	01/08/23	664KB	Share
AGN	Investor Presentation	PRICE SENSITIVE	25/07/23	2.27MB	Share
AGN	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	24/07/23	463.93KB	Share
AGN	ARG-007 Phase 2 Clinical Trial Update	PRICE SENSITIVE	19/07/23	243.05KB	Share
AGN	Ceasing to be a substantial holder		17/07/23	284.31KB	Share
AGN	ARG-007 Protects Brain Cells in Moderate TBI Model	PRICE SENSITIVE	22/06/23	1.98MB	Share
AGN	Becoming a substantial holder		20/06/23	110.14KB	Share
AGN	Becoming a substantial holder		13/06/23	89.08KB	Share
AGN	Application for quotation of securities - AGN		13/06/23	24.41KB	Share
AGN	Notification regarding unquoted securities - AGN		09/06/23	28.52KB	Share
AGN	Cleansing Notice		09/06/23	177.99KB	Share
AGN	Application for quotation of securities - AGN		09/06/23	24.88KB	Share
AGN	Release of Restricted Securities From Escrow		05/06/23	170.66KB	Share
AGN	Proposed issue of securities - AGN		02/06/23	28.11KB	Share
AGN	Argenica Successfully Completes $4.0m Placement	PRICE SENSITIVE	02/06/23	300.37KB	Share
AGN	Trading Halt	PRICE SENSITIVE	31/05/23	625.04KB	Share
AGN	Final Phase1 Clinical Trial Report	PRICE SENSITIVE	15/05/23	428.16KB	Share
AGN	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	27/04/23	462.79KB	Share
AGN	Latest Preclinical HIE Study Results	PRICE SENSITIVE	20/04/23	460.4KB	Share
AGN	Significant Non-Dilutive Funding For Preclinical HIE Studies	PRICE SENSITIVE	30/03/23	199.55KB	Share
AGN	Interim Phase 1 Safety Report Confirms Safety of ARG-007	PRICE SENSITIVE	06/03/23	298.9KB	Share
AGN	Half Yearly Report and Accounts	PRICE SENSITIVE	28/02/23	521.15KB	Share
AGN	Non-Dilutive Funding Received to Progress Alzheimers Studies	PRICE SENSITIVE	22/02/23	205.26KB	Share
AGN	Preclinical Data Shows ARG007 Inhibits a Cause of Alzheimers	PRICE SENSITIVE	09/02/23	360.51KB	Share
AGN	Investor Presentation		02/02/23	2.43MB	Share
AGN	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/01/23	386.95KB	Share
AGN	Argenica Awarded $1.2m CRC-P Grant for TBI Project	PRICE SENSITIVE	20/01/23	254.22KB	Share
AGN	Successful Completion of Phase 1 Clinical Trial Dosing	PRICE SENSITIVE	21/12/22	262.56KB	Share
AGN	Ceasing to be a substantial holder		12/12/22	104.04KB	Share
AGN	SRC Approves Commencement Of Fourth And Final Cohort Dosing	PRICE SENSITIVE	08/12/22	215.52KB	Share
AGN	Change of Director's Interest Notice		30/11/22	268.52KB	Share
AGN	Notification regarding unquoted securities - AGN		30/11/22	28.22KB	Share
AGN	Phase 1 Clinical Trial Progress Update	PRICE SENSITIVE	25/11/22	254.11KB	Share
AGN	AGM Presentation		25/11/22	1.11MB	Share
AGN	Results of Annual General Meeting		25/11/22	244.5KB	Share
AGN	Safety Review Committee Approves Third Cohort Commencement	PRICE SENSITIVE	18/11/22	216.54KB	Share
AGN	Sentinel Subjects Dosed in Second Cohort of Phase 1 Trial	PRICE SENSITIVE	07/11/22	190.99KB	Share
AGN	Safety Review Committee Approves Second Cohort	PRICE SENSITIVE	02/11/22	194.92KB	Share
AGN	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	31/10/22	384.27KB	Share
AGN	No Serious Safety Issues Observed in First Cohort	PRICE SENSITIVE	26/10/22	189.76KB	Share
AGN	Notice of Annual General Meeting/Proxy Form		21/10/22	627.57KB	Share
AGN	Investor Presentation		20/10/22	2.7MB	Share
AGN	First Healthy Adult Subject Dosed in Phase 1 Trial of ARG007	PRICE SENSITIVE	17/10/22	190.48KB	Share
AGN	Argenica Receives $1.38m R&D Tax Incentive Cash Refund	PRICE SENSITIVE	04/10/22	171.67KB	Share
AGN	Further Positive Preclinical Results for ARG-007 In HIE	PRICE SENSITIVE	29/09/22	486.34KB	Share
AGN	Date of AGM and Closing Date for Director Nominations		16/09/22	186.81KB	Share
AGN	Phase 1 Clinical Trial Summary		08/09/22	202.58KB	Share
AGN	Argenica Receives Ethics Approval To Commence Phase 1 Trial	PRICE SENSITIVE	07/09/22	229.38KB	Share
AGN	Appendix 4G & Corporate Governance Statement		23/08/22	508.22KB	Share
AGN	Appendix 4E & Annual Report 30 June 2022	PRICE SENSITIVE	23/08/22	1.31MB	Share
AGN	Ethics Application Submitted for Phase 1 Trial		11/08/22	218.25KB	Share
AGN	Quarterly Activities/Appendix 4C Cash Flow Report	PRICE SENSITIVE	29/07/22	453.67KB	Share
AGN	Clinical Advisory Committee Appointment		11/07/22	190.38KB	Share
AGN	Notification regarding unquoted securities - AGN		11/07/22	28.11KB	Share
AGN	Peer Reviewed Paper Published on Preclinical Safety Study	PRICE SENSITIVE	07/07/22	212.52KB	Share

AGN DSMB Confirms Safety of First Patients Dosed
29/04/24	PRICE SENSITIVE	263.85KB	Share
AGN Quarterly Activities/Appendix 4C Cash Flow Report
24/04/24	PRICE SENSITIVE	375.6KB	Share
AGN Cleansing Notice
22/04/24		178.19KB	Share
AGN Application for quotation of securities - AGN
22/04/24		15.55KB	Share
AGN Proposed issue of securities - AGN
12/04/24		16.9KB	Share
AGN Proposed issue of securities - AGN
12/04/24		15.74KB	Share
AGN Argenica Successfully Completes $12.0m Placement
12/04/24	PRICE SENSITIVE	224.26KB	Share
AGN Trading Halt
10/04/24	PRICE SENSITIVE	298.63KB	Share
AGN Patient Dosing Milestone Achieved in Phase 2 Stroke Trial
10/04/24	PRICE SENSITIVE	275.78KB	Share
AGN First Patient Dosed in Phase 2 Stroke Trial of ARG-007
28/03/24	PRICE SENSITIVE	289.42KB	Share
AGN FDA Grants Rare Pediatric Disease Designation For HIE
25/03/24	PRICE SENSITIVE	203.44KB	Share
AGN Application for quotation of securities - AGN
07/03/24		15.58KB	Share
AGN Half Yearly Report and Accounts
28/02/24	PRICE SENSITIVE	706.71KB	Share
AGN Application for quotation of securities - AGN
16/02/24		15.58KB	Share
AGN Phase 2 Manufacturing Completed & Trial Update
12/02/24	PRICE SENSITIVE	252.98KB	Share
AGN Cleansing Notice
02/02/24		190.16KB	Share
AGN Application for quotation of securities - AGN
02/02/24		24.9KB	Share
AGN Quarterly Activities/Appendix 4C Cash Flow Report
31/01/24	PRICE SENSITIVE	427.2KB	Share
AGN Phase 2 Stroke Clinical Trial Update
14/12/23	PRICE SENSITIVE	275.23KB	Share
AGN AGM Presentation
01/12/23		3.16MB	Share
AGN Initial Director's Interest Notice
01/12/23		263.51KB	Share
AGN Final Director's Interest Notice
01/12/23		253.78KB	Share
AGN Amended Constitution
01/12/23		599.05KB	Share
AGN Results of Annual General Meeting
01/12/23		244.69KB	Share
AGN Appointment of Non-Executive Chair
30/11/23	PRICE SENSITIVE	196.34KB	Share
AGN Argenica Appoints VP of Business Development
22/11/23		195.34KB	Share
AGN FDA Grants Orphan Drug Designation for ARG-007 HIE Treatment
15/11/23	PRICE SENSITIVE	221.17KB	Share
AGN Argenica Receives $2.09m R&D Tax Incentive Cash Rebate
13/11/23	PRICE SENSITIVE	183.74KB	Share
AGN ARG-007 Inhibits Cause of Alzheimer's in Pre-Clinical Study
03/11/23	PRICE SENSITIVE	391.65KB	Share
AGN Board Update
27/10/23		251.03KB	Share
AGN Notice of Annual General Meeting/Proxy Form
27/10/23		705.69KB	Share
AGN Quarterly Activities/Appendix 4C Cash Flow Report
26/10/23	PRICE SENSITIVE	445.53KB	Share
AGN Investor Presentation
25/10/23		1.78MB	Share
AGN Preclinical HIE Study - ARG007 Effective Stand-Alone Therapy
18/10/23	PRICE SENSITIVE	456.12KB	Share
AGN Date of AGM & Closing Date For Director Nominations
29/09/23		200.98KB	Share
AGN Ethics Approval Received for Phase 2 Trial
12/09/23	PRICE SENSITIVE	281.35KB	Share
AGN Grant Awarded To Develop Additional Administration Route
12/09/23	PRICE SENSITIVE	254.53KB	Share
AGN Presentation - Fetal and Neonatal Scientific Conference
04/09/23		1.49MB	Share
AGN Presentation - Stroke 2023 Scientific Conference
24/08/23		2.05MB	Share
AGN Positive FDA Feedback Following Pre-Ind Meeting
23/08/23	PRICE SENSITIVE	219.86KB	Share
AGN Appendix 4G & Corporate Governance Statement
23/08/23		515.83KB	Share
AGN Appendix 4E & Annual Report 30 June 2023
23/08/23	PRICE SENSITIVE	1020.23KB	Share
AGN Response to ASX Aware Query
18/08/23	PRICE SENSITIVE	354.09KB	Share
AGN Cleansing Notice
03/08/23		177.85KB	Share
AGN Application for quotation of securities - AGN
03/08/23		24.8KB	Share
AGN ARG-007 Prevents Uptake & Aggregation of Key Protein
01/08/23	PRICE SENSITIVE	664KB	Share
AGN Investor Presentation
25/07/23	PRICE SENSITIVE	2.27MB	Share
AGN Quarterly Activities/Appendix 4C Cash Flow Report
24/07/23	PRICE SENSITIVE	463.93KB	Share
AGN ARG-007 Phase 2 Clinical Trial Update
19/07/23	PRICE SENSITIVE	243.05KB	Share
AGN Ceasing to be a substantial holder
17/07/23		284.31KB	Share
AGN ARG-007 Protects Brain Cells in Moderate TBI Model
22/06/23	PRICE SENSITIVE	1.98MB	Share
AGN Becoming a substantial holder
20/06/23		110.14KB	Share
AGN Becoming a substantial holder
13/06/23		89.08KB	Share
AGN Application for quotation of securities - AGN
13/06/23		24.41KB	Share
AGN Notification regarding unquoted securities - AGN
09/06/23		28.52KB	Share
AGN Cleansing Notice
09/06/23		177.99KB	Share
AGN Application for quotation of securities - AGN
09/06/23		24.88KB	Share
AGN Release of Restricted Securities From Escrow
05/06/23		170.66KB	Share
AGN Proposed issue of securities - AGN
02/06/23		28.11KB	Share
AGN Argenica Successfully Completes $4.0m Placement
02/06/23	PRICE SENSITIVE	300.37KB	Share
AGN Trading Halt
31/05/23	PRICE SENSITIVE	625.04KB	Share
AGN Final Phase1 Clinical Trial Report
15/05/23	PRICE SENSITIVE	428.16KB	Share
AGN Quarterly Activities/Appendix 4C Cash Flow Report
27/04/23	PRICE SENSITIVE	462.79KB	Share
AGN Latest Preclinical HIE Study Results
20/04/23	PRICE SENSITIVE	460.4KB	Share
AGN Significant Non-Dilutive Funding For Preclinical HIE Studies
30/03/23	PRICE SENSITIVE	199.55KB	Share
AGN Interim Phase 1 Safety Report Confirms Safety of ARG-007
06/03/23	PRICE SENSITIVE	298.9KB	Share
AGN Half Yearly Report and Accounts
28/02/23	PRICE SENSITIVE	521.15KB	Share
AGN Non-Dilutive Funding Received to Progress Alzheimers Studies
22/02/23	PRICE SENSITIVE	205.26KB	Share
AGN Preclinical Data Shows ARG007 Inhibits a Cause of Alzheimers
09/02/23	PRICE SENSITIVE	360.51KB	Share
AGN Investor Presentation
02/02/23		2.43MB	Share
AGN Quarterly Activities/Appendix 4C Cash Flow Report
31/01/23	PRICE SENSITIVE	386.95KB	Share
AGN Argenica Awarded $1.2m CRC-P Grant for TBI Project
20/01/23	PRICE SENSITIVE	254.22KB	Share
AGN Successful Completion of Phase 1 Clinical Trial Dosing
21/12/22	PRICE SENSITIVE	262.56KB	Share
AGN Ceasing to be a substantial holder
12/12/22		104.04KB	Share
AGN SRC Approves Commencement Of Fourth And Final Cohort Dosing
08/12/22	PRICE SENSITIVE	215.52KB	Share
AGN Change of Director's Interest Notice
30/11/22		268.52KB	Share
AGN Notification regarding unquoted securities - AGN
30/11/22		28.22KB	Share
AGN Phase 1 Clinical Trial Progress Update
25/11/22	PRICE SENSITIVE	254.11KB	Share
AGN AGM Presentation
25/11/22		1.11MB	Share
AGN Results of Annual General Meeting
25/11/22		244.5KB	Share
AGN Safety Review Committee Approves Third Cohort Commencement
18/11/22	PRICE SENSITIVE	216.54KB	Share
AGN Sentinel Subjects Dosed in Second Cohort of Phase 1 Trial
07/11/22	PRICE SENSITIVE	190.99KB	Share
AGN Safety Review Committee Approves Second Cohort
02/11/22	PRICE SENSITIVE	194.92KB	Share
AGN Quarterly Activities/Appendix 4C Cash Flow Report
31/10/22	PRICE SENSITIVE	384.27KB	Share
AGN No Serious Safety Issues Observed in First Cohort
26/10/22	PRICE SENSITIVE	189.76KB	Share
AGN Notice of Annual General Meeting/Proxy Form
21/10/22		627.57KB	Share
AGN Investor Presentation
20/10/22		2.7MB	Share
AGN First Healthy Adult Subject Dosed in Phase 1 Trial of ARG007
17/10/22	PRICE SENSITIVE	190.48KB	Share
AGN Argenica Receives $1.38m R&D Tax Incentive Cash Refund
04/10/22	PRICE SENSITIVE	171.67KB	Share
AGN Further Positive Preclinical Results for ARG-007 In HIE
29/09/22	PRICE SENSITIVE	486.34KB	Share
AGN Date of AGM and Closing Date for Director Nominations
16/09/22		186.81KB	Share
AGN Phase 1 Clinical Trial Summary
08/09/22		202.58KB	Share
AGN Argenica Receives Ethics Approval To Commence Phase 1 Trial
07/09/22	PRICE SENSITIVE	229.38KB	Share
AGN Appendix 4G & Corporate Governance Statement
23/08/22		508.22KB	Share
AGN Appendix 4E & Annual Report 30 June 2022
23/08/22	PRICE SENSITIVE	1.31MB	Share
AGN Ethics Application Submitted for Phase 1 Trial
11/08/22		218.25KB	Share
AGN Quarterly Activities/Appendix 4C Cash Flow Report
29/07/22	PRICE SENSITIVE	453.67KB	Share
AGN Clinical Advisory Committee Appointment
11/07/22		190.38KB	Share
AGN Notification regarding unquoted securities - AGN
11/07/22		28.11KB	Share
AGN Peer Reviewed Paper Published on Preclinical Safety Study
07/07/22	PRICE SENSITIVE	212.52KB	Share

REFRESH

(20min delay)
Last 59.5¢		Change 0.010(1.71%)		Mkt cap ! $73.07M

Open	High	Low	Value	Volume
60.0¢	61.5¢	59.0¢	$78.11K	130.6K

Buyers (Bids)

No.	Vol.	Price($)
1	4999	59.5¢

Sellers (Offers)

Price($)	Vol.	No.
60.0¢	19915	1

View Market Depth

No.	Vol.	Price($)
1	4999	0.595
3	50000	0.570
1	25000	0.560
5	128818	0.550
1	18500	0.540

Price($)	Vol.	No.
0.600	19915	1
0.610	4777	1
0.620	11000	2
0.625	50000	1
0.660	15400	1

Last trade - 16.10pm 06/05/2024 (20 minute delay)


Last 60.5¢		Change 0.010 ( 4.31 %)
Open	High	Low	Volume
59.0¢	61.0¢	59.0¢	61277
Last updated 15.23pm 06/05/2024 ?

AGN (ASX) Chart

ARGENICA THERAPEUTICS LIMITED - Announcements

Announcements

Buyers (Bids)

Sellers (Offers)

Top Stories